NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 05/05/2026 16:00
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization32.49 mln
Float24.67 mln
Earnings Date03/26/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-0.28
Highly suspicious
Relative Strength
87
/ 100
Strongly outperforming
Debt / Equity
-1.15
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
BioXcel Therapeutics is a US-based pharmaceutical company founded in 2017 that uses AI-driven research to discover and develop treatments for brain disorders and cancer. Its approved product, IGALMI, is a dissolvable film placed under the tongue to rapidly calm agitation in adults with schizophrenia or bipolar disorder. The company has additional drug candidates in clinical trials targeting conditions such as Alzheimer's disease, opioid and alcohol dependency, prostate cancer, and pancreatic cancer. Based in New Haven, Connecticut, BioXcel works alongside leading academic institutions including Columbia University and Yale University to advance its pipeline.
